BioCryst Pharmaceuticals, Inc. announced that the Spanish Ministry for Health (Ministerio de Sanidad) has granted marketing authorization for oral, once-daily ORLADEYO® (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.34 USD | +4.71% | +19.20% | -10.85% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.85% | 1.1B | |
+2.97% | 108B | |
+10.21% | 104B | |
+2.94% | 22.33B | |
-12.77% | 22.19B | |
-7.05% | 18.69B | |
-37.64% | 17.74B | |
-6.50% | 17.64B | |
+6.00% | 14.05B | |
+37.20% | 12.51B |
- Stock Market
- Equities
- BCRX Stock
- News BioCryst Pharmaceuticals, Inc.
- BioCryst Pharmaceuticals, Inc. Announces Spanish Ministry for Health Grants Marketing Authorization for Oral, Once-Daily ORLADEYO